LDH elevation

P2, N=39, Recruiting, Ruijin Hospital

In this retrospective cohort, in-hospital mortality after percutaneous cholecystostomy was primarily associated with baseline patient vulnerability and persistent early inflammatory response after the intervention. Radiologic disease burden appeared to correlate with inflammatory recovery rather than mortality. Given the retrospective design, limited number of mortality events, and lack of external validation, these findings should be considered exploratory and hypothesis-generating. Prospective multicenter studies are warranted to further validate these observations.

The MYD88 L265P mutation is associated with poor prognosis in patients with treatment-naive DLBCL, and its VAF can reflect tumor burden. ddPCR technology facilitates the detection of MYD88 L265P mutation, which can be used for serial dynamic monitoring of DLBCL patients to guide efficacy evaluation and predict treatment outcomes.

Ten months after onset, persistent fever, neurological deterioration, hypoxemia, and sustained LDH elevation developed, and IVLBCL was finally diagnosed by a random skin biopsy. This case illustrates the extremely rare phenomenon of the repeated spontaneous remission in IVLBCL.

Therapeutically, as a clinically approved ALDH2 inhibitor, disulfiram exerts its anti-tumor effect by selective reprogramming TAMs metabolism. Overall, our findings delineate a druggable ALDH2-metabolism-epigenetics axis in antitumor immunity, nominating ALDH2 inhibition for combination immunotherapy.

The mutation frequencies of PIM1, MYD88, KMT2D, CD79B, DTX1, and MPEG1 are higher in PB-DLBCL. Patients with mutations in PIM1, MYD88, and DTX1 have a poor prognosis, whereas those with MPEG1 mutations have a favorable prognosis.

This study offers comprehensive insights into the molecular underpinnings of TC progression, highlighting the diagnostic and therapeutic potential of these hub genes and their associated regulatory networks. These findings lay a foundation for developing novel therapeutic strategies targeting these genes in TC management.

Low expression of peripheral blood CD3⁺CD56⁺CD161⁺ NKT cells is associated with increased tumor burden and bortezomib resistance in NDMM, suggesting its potential as a predictive biomarker for treatment response.

Lactate dehydrogenase (LDH) can serve as a potential biomarker for assessing lymphovascular metastasis and prognostic outcomes in endometrial cancer.

Together, these findings demonstrate critical immunometabolic distinctions between primary and immortalized microglial cells and establish that BV-2 cells do not reliably recapitulate primary microglial responses to blood breakdown products. Researchers using in vitro microglial preparations to study brain hemorrhage must carefully consider these differences when designing experiments, as reliance on BV-2 cells alone risks misrepresenting the neuroinflammatory response to IVH.

Axi-cel demonstrated substantial efficacy in Japanese patients with r/r LBCL. The 2L setting was associated with higher toxicity and numerically higher PFS.

R-CHOP immunochemotherapy achieved rapid symptom resolution and complete metabolic response on follow-up PET-CT...When random biopsies fail, multidisciplinary re-evaluation of PET-CT to identify subtle targets for image-guided biopsy is essential for definitive diagnosis. Early recognition of this triad and adoption of a hypothesis-driven biopsy strategy can significantly improve diagnostic outcomes in this elusive lymphoma.